Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation

References

• Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014 Aug 15;59(4):473–481.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016 May 19;127(20):2427–2438.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014 Jan 1;342(1):1–8.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am. 2010 Jun;24(2):319–337.
   PubMed Web of Science ®Google Scholar
• Ljungman P. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect. 1995 Dec;10(4):209–215.
   PubMedGoogle Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016 Mar;3(3):e119–27.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation [Review]. Transplantation. 2010;89(7):779–795.
   PubMed Web of Science ®Google Scholar
• Clinical pharmacology and biopharmaceutics review(s) PREVYMIS [Internet]. Silver Spring (USA): FDA; [updated 2017, Cited 2018 Nov 09]. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000ClinPharmR.pdf
   Google Scholar
• Clinical review PREVYMIS [Internet]. Silver Spring (USA): FDA; [updated 2017, cited 09/ 11/2018].Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000MedR.pdf
   Google Scholar
• European Public Assessment Report PREVYMIS [Internet]. London (UK): European Medicines Agency; [cited 09/11/2018]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004536/human_med_002200.jsp&mid=WC0b01ac058001d124
   Google Scholar
• de la Camara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):e2016031.
   PubMedGoogle Scholar
• Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008 Aug;42(4):227–240.
   PubMed Web of Science ®Google Scholar
• Bowman LJ, Melaragno JI, Brennan DC. Letermovir for the management of cytomegalovirus infection. Expert Opin Invest Drugs. 2017 Feb;26(2):235–241.
   PubMed Web of Science ®Google Scholar
• Markham A, Ganciclovir FD. An update of its therapeutic use in cytomegalovirus infection. Drugs. 1994 Sep;48(3):455–484.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011 Apr;11(4):284–292.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012 Nov;12(11):3021–3030.
   PubMed Web of Science ®Google Scholar
• Papanicolaou G, Silveira FP, Langston A, et al. Maribavir for treatment of cytomegalovirus (CMV) infections resistant or refractory to ganciclovir or foscarnet in hematopoietic stem cell transplant (SCT) or solid organ transplant (SOT) recipients: a randomized, dose-ranging, double-blind, phase 2 study. IDWeek. Advacing science, improving care.; New Orléans, LA2016 October 26–30.
   Google Scholar
• Maertens J, Cordonnier C, Jaksch P, et al. Maribavir versus valganciclovir for pre-emptive treatment of cytomegalovirus viraemia: a randomized, dose-ranging, phase 2 study among haematopoietic stem cell transplant and solid organ transplant recipients. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation; Marseille, France2017 March 16–19.
   Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26;369(13):1227–1236.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial [Conference Abstract]. Biol Blood Marrow Transplant. 2016;22(3):S23. English.
   PubMed Web of Science ®Google Scholar
• Detweiler CJ, Mueller SB, Sung AD, et al. Brincidofovir (CMX001) toxicity associated with epithelial apoptosis and crypt drop out in a hematopoietic cell transplant patient: challenges in distinguishing drug toxicity from GVHD. J Pediatr Hematol Oncol. 2018 Aug;40(6):e364–e368.
   PubMed Web of Science ®Google Scholar
• Sellar RS, Peggs KS. The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy. 2012 Apr;14(4):391–400.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011 Jan 1;52(1):49–57.
   PubMed Web of Science ®Google Scholar
• Ciaurriz M, Beloki L, Bandres E, et al. Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8(+) T cells by flow cytometry. Cytometry B Clin Cytom. 2017 Mar;92(2):153–160.
   PubMed Web of Science ®Google Scholar
• Fuji S, Einsele H, Kapp M. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Curr Opin Infect Dis. 2017 Aug;30(4):372–376.
   PubMed Web of Science ®Google Scholar
• Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 2017 Oct;31(10):2161–2171.
   PubMed Web of Science ®Google Scholar
• Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Jun;13(6):707–714.
   PubMed Web of Science ®Google Scholar
• Letermovir tablets and injection [Internet] Ltai. Dallas, Texas, USA: Drug Information; [cited 2018 july 06]. Available from: http://www.druginformation.com/RxDrugs/L/LetermovirTabletsandInjection.html
   Google Scholar
• AiCuris receives Orphan Drug Designation for Letermovir (AIC246) from FDA Wuppertal (Germany): AiCuris GmbH & Co. KG; 2012. Available from: http://www.aicuris.com/75n10AiCuris-receives-Orphan-Drug-Designation-for-Letermovir-AIC246-from-FDA.htm
   Google Scholar
• Approval letter PREVYMIS [Internet]. Silver Spring (USA): FDA; [updated 2017, cited 09/11/2018]
   Google Scholar
• Erb-Zohar K, Kropeit D, Scheuenpflug J, et al. Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multiple-dose trial. Clin Transl Sci. 2017 Nov;10(6):487–495.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377(25):2433–2444.
   PubMed Web of Science ®Google Scholar
• Bogner E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med Virol. 2002 Mar-Apr;12(2):115–127.
   PubMed Web of Science ®Google Scholar
• Borst EM, Kleine-Albers J, Gabaev I, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2013 Feb;87(3):1720–1732.
   PubMed Web of Science ®Google Scholar
• Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54(3):1290–1297.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884–10893.
   PubMed Web of Science ®Google Scholar
• Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56(2):1135–1137.
   PubMed Web of Science ®Google Scholar
• Ligat G, Cazal R, Hantz S, et al. The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev. 2018 Mar 1;42(2):137–145.
   PubMed Web of Science ®Google Scholar
• Kropeit D, McCormick D, Erb-Zohar K, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Br J Clin Pharmacol. 2017 Dec;83(12):2678–2686.
   PubMed Web of Science ®Google Scholar
• Wang L, Collins C, Kelly EJ, et al. Transporter expression in liver tissue from subjects with alcoholic or Hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metab Dispos. 2016 Nov;44(11):1752–1758.
   PubMed Web of Science ®Google Scholar
• He YJ, Zhang W, Tu JH, et al. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos. 2008;36:1453–1456.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Vildhede A, Norinder U, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740–4763.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008 Dec;64(12):1147–1161.
   PubMed Web of Science ®Google Scholar
• Kropeit D, Scheuenpflug J, Erb-Zohar K, et al. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol. 2017 Sep;83(9):1944–1953.
   PubMed Web of Science ®Google Scholar
• Sato T, Yamaguchi H, Kogawa T, et al. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. J Pharm Pharm Sci. 2014;17(4):475–484.
   PubMed Web of Science ®Google Scholar
• Eloot S, Schepers E, Barreto DV, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol. 2011 Jun;6(6):1266–1273.
   PubMed Web of Science ®Google Scholar
• Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011 May;11(5):1079–1084.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Maeda K, Sugiyama Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther. 2013 Jul;94(1):37–51.
   PubMed Web of Science ®Google Scholar
• Package Insert PREVYMIS [Internet]. Silver Spring (USA). FDA; [updated 2017, cited 09/11/2018].
   Google Scholar
• Marshall WL, McCrea JB, Macha S, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018 Mar;58(7):897-904.
   Web of Science ®Google Scholar
• Adedoyin A, Fox-Bosetti S, Fancourt C et al. Lack of pharmacokinetic interaction between single oral dosses of letermovir (MK8228) and fluconazole in healthy subjects. Poster presented at: North American ISSX meeting; 2018 July 15–19; Montréal, Canada.
   Google Scholar
• Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 8;370(19):1781–1789.
   PubMed Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014 Jan;27(1):77–86.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613.
   PubMed Web of Science ®Google Scholar
• Goldner T, Zimmermann H, Lischka P. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res. 2015 Apr;116:48–50.
   PubMed Web of Science ®Google Scholar
• Pilorge L, Burrel S, Ait-Arkoub Z, et al. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. Antiviral Res. 2014;111:8–12.
   PubMed Web of Science ®Google Scholar
• Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016 Jan 1;213(1):23–30.
   PubMed Web of Science ®Google Scholar
• Champier G, Couvreux A, Hantz S, et al. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther. 2008;13(5):643–654.
   PubMed Web of Science ®Google Scholar
• Kropeit D ea. Phase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246. Abstract 1994. 50th Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC); Boston, Massachusetts (USA) 2010 Sept 12–15.
   Google Scholar
• Templeton I, Ravenstijn P, Sensenhauser C, et al. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2016 Jan;37(1):15–27.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676–682.
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537–546.
   PubMed Web of Science ®Google Scholar